Cipla has launched a generic drug Sofosbuvir for treating chronic Hepatitis C under the brand name ‘Hepcvir’ in India. The availability of the product in other markets is subject to approvals from regulatory authorities in respective countries.

Sofusbuvir marks a new era of medicines in oral treatment of Hepatitis C, which reduce the need for injectables.

Earlier, pharmaceutical firm Dr. Reddy’s entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences Hepatitis C drug under the brand ‘Resof’ in India.

In India, around 12-18 million patients are estimated to be infected with Hepatitis C, which is several fold greater fold greater than those with HIV/AIDS.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.